Pharmanutra Future Growth

Future criteria checks 3/6

Pharmanutra is forecast to grow earnings and revenue by 19.4% and 10.8% per annum respectively while EPS is expected to grow by 19.5% per annum.

Key information

19.4%

Earnings growth rate

19.5%

EPS growth rate

Personal Products earnings growth	6.9%
Revenue growth rate	10.8%
Future return on equity	n/a
Analyst coverage	Low
Last updated	12 Sep 2023

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

BATS-CHIXE:PHNM - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	131	22	21	25	2
12/31/2024	115	18	17	21	2
12/31/2023	98	14	2	14	2
6/30/2023	93	14	-19	9	N/A
3/31/2023	88	17	-15	11	N/A
12/31/2022	83	15	-9	14	N/A
9/30/2022	79	16	6	16	N/A
6/30/2022	76	15	10	19	N/A
3/31/2022	73	15	14	20	N/A
12/31/2021	68	14	15	20	N/A
9/30/2021	65	14	13	16	N/A
6/30/2021	60	11	12	15	N/A
3/31/2021	57	14	13	15	N/A
12/31/2020	57	14	10	12	N/A
9/30/2020	58	14	11	11	N/A
6/30/2020	58	14	7	11	N/A
3/31/2020	55	9	4	9	N/A
12/31/2019	54	8	7	12	N/A
9/30/2019	49	8	3	8	N/A
6/30/2019	50	9	7	9	N/A
3/31/2019	48	9	6	8	N/A
12/31/2018	47	9	6	6	N/A
9/30/2018	44	8	5	6	N/A
6/30/2018	41	7	5	6	N/A
3/31/2018	40	6	5	6	N/A
12/31/2017	38	6	5	6	N/A
9/30/2017	37	5	N/A	N/A	N/A
6/30/2017	35	5	N/A	N/A	N/A
3/31/2017	34	4	N/A	N/A	N/A
12/31/2016	33	4	N/A	6	N/A
12/31/2015	26	3	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHNM's forecast earnings growth (19.4% per year) is above the savings rate (1.4%).

Earnings vs Market: PHNM's earnings (19.4% per year) are forecast to grow faster than the UK market (10.3% per year).

High Growth Earnings: PHNM's earnings are forecast to grow, but not significantly.

Revenue vs Market: PHNM's revenue (10.8% per year) is forecast to grow faster than the UK market (4% per year).

High Growth Revenue: PHNM's revenue (10.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PHNM's Return on Equity is forecast to be high in 3 years time

Pharmanutra Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Recent updates

Pharmanutra S.p.A. to Report Fiscal Year 2023 Results on Mar 15, 2024

Less than half of directors are independent

First quarter 2023 earnings released

Upcoming dividend of €0.80 per share at 1.6% yield

Less than half of directors are independent

Less than half of directors are independent

Full year 2022 earnings released: EPS: €1.56 (vs €1.42 in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

Pharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023

Less than half of directors are independent

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: €0.49 (vs €0.47 in 2Q 2021)

Less than half of directors are independent

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million.

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

PharmaNutra S.P.A. Announces European Union Authorises Marketing of CFAs as Novel Food

Less than half of directors are independent

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies